Neuraminidase inhibitors in patients with underlying airways disease

American Journal of Respiratory Medicine

Volumn 1, Issue 2, 2002, Pages 85-90

  Williamson, John C ^a   Pegram, P Samuel ^a  

^a WAKE FOREST BAPTIST HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; INFLUENZA VACCINE; OSELTAMIVIR; PLACEBO; RELENZA ROTADISK; RIMANTADINE; SIALIDASE INHIBITOR; VIRUS ANTIGEN; ZANAMIVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AGED; ARTICLE; ASTHMA; ATAXIA; ATTENTION DEFICIT DISORDER; BRONCHITIS; BRONCHOSPASM; BRONCHUS HYPERREACTIVITY; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONFUSION; DISEASE EXACERBATION; DROWSINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HEALTH CARE COST; HEART DISEASE; HOSPITALIZATION; HUMAN; IMMUNE DEFICIENCY; INFECTION SENSITIVITY; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A; INFLUENZA VIRUS B; INSOMNIA; KIDNEY FAILURE; MALIGNANT NEOPLASTIC DISEASE; MORBIDITY; MORTALITY; NAUSEA; NERVOUSNESS; PNEUMONIA; POSTMARKETING SURVEILLANCE; POWDER INHALER; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; SYMPTOMATOLOGY; TREMOR; UNITED STATES; VERTIGO; VOMITING; WHEEZING;

EID: 0042888617     PISSN: 11756365     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03256597     Document Type: Article

References (39)

1. WHO urges influenza vaccination for northern hemisphere [online]. Available from URL: http://www.who.int/inf/en/pr-2002-08.htm [Accessed 2002 Feb 2]
2. Centers for Disease Control and Prevention. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2001; 50: 1-46
3. Glezen WP, Decker M, Perrotta DM. Survey of underlying conditions of persons hospitalized with acute respiratory disease during influenza epidemics in Houston, 1978-1981. Am Rev Respir Dis 1987; 136: 550-5
4. Neuzil KM, Reed GW, Mitchel EF, et al. Influenza-associated morbidity and mortality in young and middle-aged women. JAMA 1999; 281: 901-7
5. Izurieta HS, Thompson WW, Kramarz P, et al. Influenza and the rates of hospitalization for respiratory disease among infants and young children. N Engl J Med 2000; 342: 232-9
6. Carrat F, Valleron A. Influenza mortality among the elderly in France, 1980-90: how many deaths may have been avoided through vaccination? J Epidemiol Community Health 1995; 49: 419-25
7. Dreitlein WB, Maratos J, Brocavich J. Zanamivir and oseltamivir: two new options for the treatment and prevention of influenza. Clin Ther 2001; 23: 327-55
8. Clementsen P, Jensen CB, Hannoun C, et al. Influenza A virus potentiates basophil histamine release caused by endotoxin-induced complement activation. Allergy 1988; 43: 93-9
9. Utell MJ, Aquilina AT, Hall WJ, et al. Development of airway reactivity to nitrates in subjects with influenza. Am Rev Respir Dis 1980; 121: 233-41
10. Kondo S, Abe K. The effects of influenza virus infection on FEV1 in asthmatic children. Chest 1991; 100: 1235-8
11. Smith CB, Kanner RE, Golden CA, et al. Effect of viral infections on pulmonary function in patients with chronic obstructive pulmonary diseases. J Infect Dis 1980; 141: 271-80
12. Camner P, Jarstrand C, Philipson K. Tracheobronchial clearance in patients with influenza. Am Rev Resp Dis 1973; 108: 131-5
13. Levandowski RA, Gerrity TR, Garrard CS. Modifications of lung clearance mechanisms by acute influenza A infection. J Lab Clin Med 1985; 106: 428-32
14. The MIST Study Group. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. Lancet 1998; 352: 1877-81
15. Hayden FG, Osterhaus ADME, Treanor JJ, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. N Engl J Med 1997; 337: 874-80
16. Monto AS, Fleming DM, Henry D, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections. J Infect Dis 1999; 180: 254-61
17. Makela MJ, Pauksens K, Rostila T, et al. Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomized, double-blind, placebo-controlled European study. J Infection 2000; 40: 42-8
18. Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. JAMA 2000; 283: 1016-24
19. Nicholson KG, Aoki FY, Osterhaus ADME, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Lancet 2000; 355: 1845-50
20. Aoki FY, Fleming DM, Griffin AD, et al. Impact of zanamivir treatment on productivity, health status and healthcare resource use in patients with influenza. Pharmacoeconomics 2000; 17: 187-95
21. Mauskopf JA, Cates SC, Griffin AD, et al. Cost effectiveness of zanamivir for the treatment of influenza in a high risk population in Australia. Pharmacoeconomics 2000; 17: 611-20
22. Kucers A, Crowe S, Grayson ML, et al. The use of antibiotics: a clinical review of antibacterial, antifungal and antiviral drugs. Oxford: Butterworth-Heinemann; 1997
23. Hayden FG, Hoffman HE, Spyker DA. Differences in side effects of amantadine hydrochloride and rimantadine hydrochloride relate to differences in pharmacokinetics. Antimicrob Agents Chemother 1983; 23: 458-64
24. Gubareva LV, Kaiser L, Hayden FG. Influenza virus neuraminidase inhibitors. Lancet 2000; 355: 827-35
25. Centers for Disease Control and Prevention. 2000-2001 influenza season summary [online]. Available from URL: [Accessed 2001 Sep 28] http://www.cdc.gov/ncidod/diseases/flu/weeklyarchives2000-2001/ 00-01summary.htm
26. Daniel MJ, Barnett JM, Pearson BA. The low potential for drug interactions with zanamivir. Clin Pharmacokinet 1999; 36 Suppl. 1: 41-50
27. Cass LMR, Brown J, Pickford M, et al. Pharmacoscintigraphic evaluation of lung disposition of inhaled zanamivir in healthy volunteers. Clin Pharmacokinet 1999; 36 Suppl. 1: 21-31
28. Lumpkin MM. Food and Drug Administration public health advisory, subject: safe and appropriate use of influenza drugs [online]. Available from URL: http://www.fda.gov/cder/drug/advisory/influenza.htm [Accessed 2001 Sep 28]
29. Williamson JC, Pegram PS. Respiratory distress associated with zanamivir. N Engl J Med 2000; 342: 661-2
30. Relenza [package insert]. Research Triangle Park (NC): Glaxo Wellcome, 2001
31. Cass LMR, Gunawardena KA, Macmahon MM, et al. Pulmonary function and airway responsiveness in mild to moderate asthmatics given repeated inhaled doses of zanamivir. Respir Med 2000; 94: 166-73
32. Data on file, GlaxoSmithKline, 2001
33. Murphy KR, Eivindson A, Pauksens K, et al. Efficacy and safety of inhaled zanamivir for the treatment of influenza in patients with asthma or chronic obstructive pulmonary disease. Clin Drug Invest 2000; 20: 337-49
34. Lalezari J, Campion K, Keene O, et al. Zanamivir for the treatment of influenza A and B infection in high-risk patients. Arch Intern Med 2001; 161: 212-7
35. Gravenstein S, Johnston SL, Loeschel E, et al. Zanamivir: a review of clinical safety in individuals at high risk of developing influenza-related complications. Drug Saf 2001; 24: 1113-25
36. Hayden FG, Treanor JJ, Fritz RS, et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA 1999; 282: 1240-6
37. Hayden FG, Atmar RL, Schilling M, et al. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med 1999; 341: 1336-43
38. Welliver R, Monto AS, Carewicz O, et al. Effectiveness of oseltamivir in preventing influenza in household contacts. JAMA 2001; 285: 748-54
39. Tamiflu [package insert]. Nutley (NJ): Roche Laboratories, 2000